JOP20190056B1 - مركبات للاستخدام في علاج القصور الكلوي الحاد - Google Patents
مركبات للاستخدام في علاج القصور الكلوي الحادInfo
- Publication number
- JOP20190056B1 JOP20190056B1 JOP/2019/0056A JOP20190056A JOP20190056B1 JO P20190056 B1 JOP20190056 B1 JO P20190056B1 JO P20190056 A JOP20190056 A JO P20190056A JO P20190056 B1 JOP20190056 B1 JO P20190056B1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- treatment
- kidney injury
- acute kidney
- acute
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404390P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055400 WO2018067857A1 (en) | 2016-10-05 | 2017-10-05 | Methods of treating acute kidney injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JOP20190056A1 JOP20190056A1 (ar) | 2019-03-24 |
| JOP20190056B1 true JOP20190056B1 (ar) | 2022-03-15 |
Family
ID=60153507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0056A JOP20190056B1 (ar) | 2016-10-05 | 2017-10-05 | مركبات للاستخدام في علاج القصور الكلوي الحاد |
Country Status (33)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX392524B (es) | 2015-10-07 | 2025-03-24 | Salk Inst Biological Studies | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar |
| BR112018069930B1 (pt) * | 2016-04-13 | 2024-02-20 | Mitobridge, Inc | Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica |
| EP3523283B1 (en) | 2016-10-05 | 2021-06-09 | Mitobridge, Inc. | Crystalline and salt forms of ppar agonist compounds |
| US20220323416A1 (en) * | 2019-07-19 | 2022-10-13 | Vifor (International) Ag | Ferroportin-Inhibitors For The Use In The Prevention And Treatment Of Kidney Injuries |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| KR20240019753A (ko) * | 2021-03-08 | 2024-02-14 | 아비오닉스 파마 에스에이 | 간 질환을 치료하는 데 유용한 화합물 |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN115813901B (zh) * | 2022-10-20 | 2024-10-22 | 南京市儿童医院 | 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE028213T2 (en) * | 2003-09-19 | 2016-12-28 | Janssen Pharmaceutica Nv | 4 - ((Phenoxyalkyl) thio) -phenoxyacetic acid for use in the treatment of PPAR-delta-mediated conditions |
| AU2005247473A1 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Substituted triazoles as modulators of PPAR and methods of their preparation |
| RU2320341C1 (ru) * | 2006-06-13 | 2008-03-27 | Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук | Средство для лечения острой обструкции верхних мочевыводящих путей |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| BRPI0920170A2 (pt) * | 2008-10-17 | 2016-06-21 | Metabolex Inc | métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método. |
| US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| WO2014138738A1 (en) * | 2013-03-08 | 2014-09-12 | Abbive Inc. | Methods of treating acute kidney injury |
| EP2981522A4 (en) * | 2013-04-05 | 2016-08-31 | Salk Inst For Biological Studi | PPAR AGONISTS |
| EP2862574A1 (en) * | 2013-10-15 | 2015-04-22 | Sanofi | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
| CN110007084B (zh) * | 2013-12-03 | 2022-11-18 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| WO2016057656A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases |
| WO2016057658A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| MX392524B (es) * | 2015-10-07 | 2025-03-24 | Salk Inst Biological Studies | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar |
-
2017
- 2017-10-05 MY MYPI2019001558A patent/MY192385A/en unknown
- 2017-10-05 ES ES17787773T patent/ES2859487T3/es active Active
- 2017-10-05 LT LTEP17787773.5T patent/LT3522880T/lt unknown
- 2017-10-05 RU RU2019111421A patent/RU2753607C2/ru active
- 2017-10-05 MD MDE20190903T patent/MD3522880T2/ro unknown
- 2017-10-05 SM SM20210111T patent/SMT202100111T1/it unknown
- 2017-10-05 EP EP17787773.5A patent/EP3522880B1/en active Active
- 2017-10-05 WO PCT/US2017/055400 patent/WO2018067857A1/en not_active Ceased
- 2017-10-05 KR KR1020197012516A patent/KR20190062502A/ko not_active Ceased
- 2017-10-05 JP JP2019518278A patent/JP7065839B2/ja active Active
- 2017-10-05 JO JOP/2019/0056A patent/JOP20190056B1/ar active
- 2017-10-05 SG SG11201901925RA patent/SG11201901925RA/en unknown
- 2017-10-05 CN CN201780062021.8A patent/CN109789117B/zh active Active
- 2017-10-05 US US16/334,384 patent/US20210283116A1/en not_active Abandoned
- 2017-10-05 BR BR112019005539-8A patent/BR112019005539A2/pt not_active Application Discontinuation
- 2017-10-05 MA MA46459A patent/MA46459B1/fr unknown
- 2017-10-05 AU AU2017340760A patent/AU2017340760B2/en not_active Ceased
- 2017-10-05 HR HRP20210294TT patent/HRP20210294T1/hr unknown
- 2017-10-05 UA UAA201904011A patent/UA124019C2/uk unknown
- 2017-10-05 PT PT177877735T patent/PT3522880T/pt unknown
- 2017-10-05 RS RS20210203A patent/RS61573B1/sr unknown
- 2017-10-05 PL PL17787773T patent/PL3522880T3/pl unknown
- 2017-10-05 MX MX2019003949A patent/MX387518B/es unknown
- 2017-10-05 HU HUE17787773A patent/HUE053557T2/hu unknown
- 2017-10-05 DK DK17787773.5T patent/DK3522880T3/da active
- 2017-10-05 SI SI201730653T patent/SI3522880T1/sl unknown
- 2017-10-05 TW TW106134387A patent/TWI778982B/zh active
- 2017-10-05 CA CA3036723A patent/CA3036723A1/en active Pending
-
2019
- 2019-03-20 ZA ZA2019/01743A patent/ZA201901743B/en unknown
- 2019-04-01 IL IL265749A patent/IL265749A/en unknown
- 2019-04-03 PH PH12019500725A patent/PH12019500725A1/en unknown
- 2019-05-03 CO CONC2019/0004561A patent/CO2019004561A2/es unknown
-
2021
- 2021-02-23 CY CY20211100148T patent/CY1124759T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3720553C0 (en) | PHOTOBIOMODULATION DEVICE FOR THE TREATMENT OF A RETINAL DISEASE | |
| EA201790737A1 (ru) | Комбинированная терапия | |
| LT3672954T (lt) | Junginiai, jų druskos ir jų naudojimas ligoms gydyti | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| IL270511A (en) | Combination therapies using niraparib and pembrolizumab for treating cancer | |
| LT3283527T (lt) | Kompleksinė terapija vėžio gydymui | |
| EP3875139C0 (en) | TREATMENT OF VENOUS DISEASES | |
| EP3448263A4 (en) | ELECTROTHERAPEUTIC TREATMENT | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| PH12019500725A1 (en) | Methods of treating acute kidney injury | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| ZA201900343B (en) | Self-contained treatment unit for haemodialysis treatments | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| HUE063369T2 (hu) | Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben | |
| MX388722B (es) | Compuestos para tratar el cancer de ovario. | |
| EP3720509A4 (en) | GENE THERAPY WITH A GLOBIN GENE FOR THE TREATMENT OF HEMOGLOBINOPATHIES | |
| HUE053648T2 (hu) | Gyógyászati kombinációk rák kezelésére | |
| MX2017000306A (es) | Metodos para tratar hipotension. | |
| EA201892297A1 (ru) | Способы лечения холестатических и фибротических заболеваний | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| EA201791819A1 (ru) | Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина | |
| MX382608B (es) | Tratamiento del prurito urémico. | |
| EA201891008A3 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
| CY1125266T1 (el) | To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων |